FORMULATION WITH IMPROVED BIOAVAILABILITY
The TML-6 formulation with polymethacrylate and cellulose derivatives addresses curcumin's low bioavailability, improving solubility and bioavailability for effective treatment of neurodegenerative diseases and other conditions.
Patent Information
- Application Number
- FR2024004665
- Authority / Receiving Office
- FR · FR
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2024-05-03
- Publication Date
- 2024-11-08
AI Technical Summary
Curcumin's low bioavailability and rapid metabolism hinder its therapeutic development for human diseases, particularly neurodegenerative conditions.
A formulation comprising TML-6 in an amorphous form, combined with excipients such as polymethacrylate and cellulose derivatives, enhances solubility and bioavailability, characterized by specific XRPD and DSC patterns, and administered in forms like tablets or capsules.
The formulation improves solubility and bioavailability of TML-6, leading to enhanced therapeutic effectiveness in treating neurodegenerative diseases, cancers, cardiovascular diseases, obesity, inflammatory diseases, and aging.
Smart Images

Figure 00000022_0000 
Figure 00000023_0000 
Figure 00000023_0001
Abstract
Description
Title of the invention: FORMULATION HAVING IMPROVED BIOAVAILABILITY Field of invention
[0001] The present disclosure relates to a formulation comprising a curcumin derivative. More particularly, the present disclosure relates to an oral formulation comprising a curcumin derivative, which has improved solubility, bioavailability and / or PK profile characteristics. Background of the invention
[0002] Curcumin is a major component of Curcumin longa, known generically as turmeric, which belongs to the ginger family, a perennial plant that grows naturally in India and other parts of Asia. Curcumin is effective against a wide variety of diseases such as cancers, cardiovascular diseases, obesity, liver diseases, inflammatory diseases, and aging. Although the beneficial effects of curcumin have been suggested by a series of epidemiological investigations, animal experiments, and cell line studies, the low bioavailability and rapid metabolism of curcumin have hampered the therapeutic development of curcumin for human diseases [Jager R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM: Comparative absorption of curcumin formulations. Nutr J 2014, 13:11}. Summary of the invention
[0003] The present disclosure highlights a formulation comprising a curcumin derivative having improved solubility and bioavailability characteristics and / or PK profile for the treatment and / or prevention of a neurodegenerative disease.
[0004] The present disclosure provides a formulation comprising TML-6 or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in an amorphous form, and one or more excipients, [Chem. 1] TML-6.
[0005] In one embodiment, the formulation is characterized by a differential scanning calorimetry thermogram that includes no sharp endothermic peaks.
[0006] In one embodiment, the formulation is characterized by a DSC thermogram that does not include an endothermic peak corresponding to crystalline TML-6.
[0007] In one embodiment, the formulation is characterized by a DSC thermogram that includes a broad endothermic peak at a temperature of about 50°C to about 90°C.
[0008] In one embodiment, the formulation is characterized by an X-ray powder diffraction (XRPD) pattern that is substantially continuous (without a narrow or sharp diffraction peak).
[0009] The formulation of claim 5, characterized by the XRPD pattern which does not include a 20 degree reflection (± 0.2° 20) at one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°.
[0010] The present disclosure further provides a formulation comprising from about 20% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and from about 10% (w / w) to about 80% (w / w) of one or more excipients, [Chem 1] TML-6.
[0011] In one embodiment, TML-6, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, is in amorphous form.
[0012] In one embodiment, the formulation comprises from about 70% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and from about 10% (w / w) to about 30% (w / w) of one or more excipients.
[0013] In one embodiment, the excipient(s) comprise enteric polymers.
[0014] In one embodiment, the excipient(s) comprise at least one of a polymethacrylate-based copolymer, a poly(methacrylic acid)-based copolymer, a poloxamer, and a cellulose-derived excipient.
[0015] In one embodiment, the ratio of polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer to cellulose-derived excipients is in the range of about 1:5 to about 5:1.
[0016] In one embodiment, the amount of the polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymers is in the range of about 10% to about 70% (w / w), and the amount of the cellulose-derived excipient is in the range of about 10% to about 70% (w / w).
[0017] In one embodiment, the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer are selected from the group consisting of: poly(methacrylic acid, methyl methacrylate) 1 / 1, poly(methacrylic acid, ethyl acrylate) 1 / 1, poly(methacrylic acid, methyl methacrylate) 1 / 2, poly(methacrylic acid, methyl methacrylate) 1 / 2, a polymer of methyl acrylate, methyl methacrylate and methacrylic acid, poly(butyl methacrylate-co-2-dimethylaminoethyl methacrylate-co-methyl methacrylate) 1 / 2 / 1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.2, poly(ethyl acrylate,methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethyl ethanaminium chloride) 1 / 2 / 0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethyl ethanaminium chloride) 1 / 2 / 0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethyl ethanaminium chloride) 1 / 2 / 0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium) 1 / 2 / 0.1, poly(ethyl acrylate, methyl methacrylate) with 0.7% PEG stearyl ether 2 / 1, poly(ethyl acrylate, methyl methacrylate) with 1.5% nonoxynol 2 / 1 and poly(ethyl acrylate, methyl methacrylate) with 1.5% (nonoxynol) 2 / 1, and combinations thereof.
[0018] In one embodiment, the cellulose-derived excipient is selected from the group consisting of cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, a cellulose ester derivative, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropylmethylcellulose phthalate, microcrystalline cellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose.
[0019] In one embodiment, the formulation is in the form of tablets, granules, capsules or spray-dried powders.
[0020] The present disclosure also provides a pharmaceutical composition comprising the formulation and one or more additional excipients.
[0021] In another embodiment, the additional excipient(s) include, but are not limited to, diluents, disintegrants, binding agents, lubricants, and glidants.
[0022] The present disclosure further provides a method for preventing and / or treating a neurodegenerative disease, a liver disease, cancer, a cardiovascular disease, obesity, an inflammatory disease or aging in a subject in need of such treatment, comprising administering to said subject the pharmaceutical formulation or composition.
[0023] In one embodiment, the neurodegenerative disease is amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's chorea, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease, or a prion disease. Brief description of the drawings
[0024] [Fig. 1] [Fig. 1] shows the X-ray powder diffraction (XRPD) pattern of TML-6.
[0025] [Fig.2] [Fig.2] shows the XRPD pattern of TML-6 formulation E13.
[0026] [Fig.3] [Fig.3] shows DSC thermograms of TML-6 and formulations E14 to E17 of TML-6.
[0027] [Fig.4] [Fig.4] shows DSC thermograms of TML-6 and the formulation E04 of TML-6.
[0028] [Fig.5] [Fig.5] shows DSC thermograms of TML-6 and formulations E10 and E12 of TML-6.
[0029] [Fig.6] [Fig.6] shows the plasma concentration-time profiles of TML-6 in rats (mean) after a single administration of TML-6 and TML-6 formulations E02, E10, E12 and E13 from 0 hours to 10 hours.
[0030] [Fig.7] [Fig.7] shows the plasma concentration-time profiles of TML-6 in dogs (mean) after a single administration of TML-6 and TML-6 formulations E02, E10, E12 and E13 from 0 hours to 25 hours. Detailed description of the invention
[0031] The present invention may be more readily understood by reference to the following detailed description of various embodiments of the invention, examples, and chemical drawings and tables with their corresponding descriptions. It is appropriate to understand that, unless otherwise indicated by the claims, the invention is not limited to specific methods of preparation, vehicles or formulations, or to particular modes of formulating the compounds of the invention into products or compositions for topical, oral or parenteral administration, since a person of ordinary skill in the art will be aware that such things may of course vary. It is also to be understood that the terminology used herein is intended to describe particular embodiments only and is not intended to be limiting.
[0032] In this application, terms such as "a / an", "the" and "the" are not intended to refer to a single singular entity, but encompass the general class from which a specific example may be used for illustration. The terms "a / an", "the" and "the" are used herein interchangeably with the phrase "at least one". The phrases "at least one of" and "includes at least one" followed by a list refer to any of the elements in the list and any combination of two or more elements in the list. All numerical ranges include their bounds and non-integer values between the bounds, unless otherwise specified.
[0033] The term "subject", as used herein, refers to any animal, preferably a mammal, and more preferably a human. Examples of subjects include humans, non-human primates, rodents, guinea pigs, rabbits, sheep, pigs, goats, cows, horses, dogs, and cats.
[0034] The term "treat" or "treatment," as used herein, means reversing, mitigating, inhibiting the progression of, or ameliorating the disease, disorder, or condition to which such term applies, or one or more symptoms of that disease, disorder, or condition.
[0035] The term "polymer" refers to a molecule having a structure that comprises multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass.
[0036] The term "solvent" refers to a homogeneous liquid material, which may be a single compound or a combination of compounds, and which may or may not include water.
[0037] The term "vehicle" or "excipient", as used herein, refers to any substance, which is not itself a therapeutic agent, used as a carrier and / or diluent and / or adjuvant, or vehicle for the delivery of a therapeutic agent to a subject, or added to a formulation to improve its handling or storage properties or to enable or facilitate the formulation of a unit dose of the composition into a discrete article such as a capsule or tablet suitable for oral administration.
[0038] As used herein, the term "pharmaceutically acceptable" is defined herein to refer to the compounds, materials, compositions and / or dosage forms which, within the scope of good medical judgment, are suitable for contact with the tissues of a subject, e.g., a mammal or a human, without excessive toxicity, allergic irritation response, and other problematic complications.
[0039] The compound TML-6 as described herein is a curcumin derivative or a synthetic curcumin derivative, which has anti-inflammatory properties involved in multiple mechanisms of AD pathogenesis, reveals significantly better activity than curcumin in reducing brain A[3 level, and a better anti-inflammatory effect than curcumin. TML-6 may exist as a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
[0040] In certain embodiments, the present disclosure provides a formulation comprising TML-6 and a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof in an amorphous form or a crystalline form, and one or more excipients, [Chem 1] TML-6.
[0041] In some embodiments, TML-6 is in an amorphous form. Without wishing to be bound by any theory, Applicant has surprisingly found that the amorphous form of TML-6 has better solubility, dissolution and / or bioavailability characteristics. The amorphous form of TML-6 can be detected and determined by any known methods, such as X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC).
[0042] For example, the formulation may be characterized by a differential scanning calorimetry thermogram that does not include any sharp endothermic peak, by a DSC thermogram that does not include an endothermic peak corresponding to crystalline TML-6 (at about 132 ± 5°C), or by a DSC thermogram that includes a broad endothermic peak (e.g., at a temperature of about 50°C to about 90°C). In some embodiments, the broad endothermic peak may correspond to the one or more excipients. In another appearance, the formulation may be characterized by an X-ray powder diffraction (XRPD) pattern that is substantially continuous (without a narrow or sharp diffraction peak), or by an XRPD pattern that does not include a 20 degree reflection (± 0.2° 20) at one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°.
[0043] The particle size of the drug, the particle size of TML-6, is controlled by drying and / or milling / sieving (non-limiting examples of which are described below). The particle size may also be made powdery by roller compacting and milling / sieving. In the present disclosure, at least 60% of the particle size distribution of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, in the formulation, is less than 150 μm. The particle size distribution may be used by sieve analysis, photon correlation spectroscopy, or laser diffraction (International Standard ISO 13320-1), or by electronic detection zone, light obstruction, sedimentation, or microscopy procedures that are well known to those skilled in the art.
[0044] One or more excipients are combined with TML-6 to prepare the formulation as described herein. The formulation as described herein comprises from about 20% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and from about 10% (w / w) to about 80% (w / w) of one or more excipients. In some embodiments, the formulation may comprise from about 70% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and from about 10% (W / W) to about 30% (w / w) of one or more excipients.
[0045] The one or more excipients include one or more polymethacrylate-based copolymers, poly(methacrylic acid)-based copolymers, poloxamers, and cellulose-derived excipients. Without wishing to be bound by any theory, it is believed that these excipients may increase the dissolution of TML-6 in gastric juices and / or intestinal juices, regulate the solid form of TMF-6 (preferably in amorphous form), and / or improve the PK profile of TML-6 formulations. Preferably, the amount of polymethacrylate-based copolymer is in the range of about 10% to about 70% (w / w) and the amount of cellulose-derived excipient is about 10% to about 70% (w / w). The polymethacrylate-based copolymer includes poly(methyl methacrylate) (PMMA)-based copolymers.Some embodiments of the PMMA-based copolymers include, but are not limited to, neutral, cationic, and anionic forms of PMMA-based copolymers. In some embodiments, the PMMA-based copolymers may include a copolymer based on methyl methacrylate and one or more of methacrylic acid, methacrylate esters, and . acrylate esters. In another embodiment, the PMMA is poly(methacrylic acid-co-methyl methacrylate). In certain other embodiments, the poly(methacrylic acid-co-methyl methacrylate) includes, but is not limited to, any of the methacrylic acid and methyl methacrylate-based polymers as described herein.
[0046] Some embodiments of the poly(methacrylic acid)-based copolymers include, but are limited to, copolymers of methacrylic acid with methyl acrylate, ethyl acrylate, tert-butyl acrylate, methyl methacrylate, and α-isopropylacrylamide. In other embodiments, the poly(methacrylic acid)-based copolymers may be a methacrylic acid / methyl methacrylate (1 / 1) copolymer and / or a methacrylic acid / ethyl acrylate (1 / 1)-based copolymer.
[0047] Some embodiments of the cellulose-derived excipient include, but are not limited to, cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, a cellulose ester derivative, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropylmethylcellulose phthalate, microcrystalline cellulose (MCC), hydroxyethylcellulose, and hydroxypropylmethylcellulose.
[0048] In some embodiments, the methacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer comprise poly(methacrylic acid, methyl methacrylate) 1 / 1, poly(methacrylic acid, ethyl acrylate) 1 / 1, poly(methacrylic acid, methyl methacrylate) 1 / 2, poly(methacrylic acid, methyl methacrylate) 1 / 2, a polymer of methyl acrylate, methyl methacrylate, and methacrylic acid, poly(butyl methacrylate-co-2-dimethylaminoethyl methacrylate-co-methyl methacrylate) 1 / 2 / 1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride, or methyl chloride 2-(methacryloyloxy)-N,N,N-trimethylethanaminium) 1 / 2 / 0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.2, poly(ethyl acrylate, methyl methacrylate,2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.1, poly(ethyl acrylate, methacrylate, methyl, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.1, poly(ethyl acrylate, methyl methacrylate) with 0.7% PEG stearyl ether 2 / 1, poly(ethyl acrylate, methyl methacrylate) with 1.5% nonoxynol 2 / 1 and poly(ethyl acrylate, methyl methacrylate) with 1.5% (nonoxynol) 2 / 1, and combinations thereof.
[0049] In some embodiments, the ratio of polymethacrylate-based copolymers and / or poly(methacrylic acid)-based copolymers to cellulose-derived excipients is in the range of about 1:5 to about 5:1. For example, the ratio of poly(methacrylic acid)-based copolymer to cellulose-derived excipient is in the range of about 1 / 5 to about 5 / 1, such as 5 / 25, 6 / 24, 7 / 23, 8 / 22, 9 / 21, 10 / 20, 11 / 19, 12 / 18, 13 / 17, 14 / 16, 15 / 15, 16 / 14, 17 / 13, 18 / 12, 19 / 11, 20 / 10, 21 / 9, 22 / 8, 23 / 7, 24 / 6 or 25 / 5.
[0050] In some embodiments, the excipient(s) comprise one or more polymeric materials, such as a polysorbate and / or a poloxamer. Some embodiments of the polysorbate include, but are not limited to, Tween 20, Tween 40, Tween 60, Tween 80, and Tween 85. Some embodiments of the poloxamer include, but are not limited to, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 238, and poloxamer 407. These polymeric materials may be used alone or with one or more polymethacrylate-based copolymers and / or cellulose-derived excipients.
[0051] The formulation as described herein may be prepared by ball milling, wet granulation, direct compression and dry granulation, melt extrusion, or spray drying. In some embodiments, the formulation may be in the form of granules, spray-dried powders, capsules, or tablets.
[0052] The formulation as described herein may optionally be combined with one or more additional excipients to form a pharmaceutical composition. In one embodiment, the pharmaceutical composition may be a tablet or a capsule. Some embodiments of the additional excipient(s) include, but are not limited to, diluents, disintegrants, binders, lubricants, and glidants.
[0053] Lubricants are typically added to prevent tablet-forming materials from adhering to the punches, minimize friction during tablet compression, and allow removal of the compressed tablet from the die. Examples of pharmaceutically acceptable lubricants and pharmaceutically acceptable glidants include, but are not limited to, colloidal silica, magnesium trisilicate, starches, talc, tribasic calcium phosphate, magnesium stearate, aluminum stearate, calcium stearate, magnesium carbonate, magnesium oxide, polyethylene glycol, powdered cellulose and microcrystalline cellulose.
[0054] Binders are agents that impart cohesive qualities to the powdered material. Commonly used binders include starch, and sugars such as sucrose, glucose, dextrose, and lactose. Examples of pharmaceutically acceptable binders include, but are not limited to, starches; celluloses and their derivatives, e.g., microcrystalline cellulose, hydroxypropylcellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose; sucrose; dextrose; corn syrup; polysaccharides; and gelatin.
[0055] Diluents are added to increase the bulk mass of the mixture resulting in a size convenient for compression. Examples of pharmaceutically acceptable fillers and pharmaceutically acceptable diluents include, but are not limited to, icing sugar, compressible sugar, dextrates, dextrin, dextrose, lactose, mannitol, microcrystalline cellulose, powdered cellulose, sorbitol, sucrose, and talc.
[0056] Disintegrants are often incorporated to ensure an acceptable disintegration rate of the tablet. Typical disintegrants include starch derivatives and carboxymethylcellulose salts. Examples of pharmaceutically acceptable disintegrants include, but are not limited to, starches; clays, celluloses, alginates; gums; crosslinked polymers, e.g., crosslinked polyvinylpyrrolidone (PVP), crosslinked calcium carboxymethylcellulose, and crosslinked sodium carboxymethylcellulose; soy polysaccharides; and guar gum.
[0057] Examples of glidants include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, and sodium stearyl fumarate.
[0058] Other examples of useful excipients are described in Handbook of pharmaceutical excipients, 3rd edition, edited by A.H. Kibbe, published by: American Pharmaceutical Association, Washington DC, ISBN: 0-917330-96-X, or Handbook of Pharmaceutical Excipients (4th edition), edited by Raymond C. Rowe - editor: Science and Practice.
[0059] The present disclosure also provides a method for preventing and / or treating a neurodegenerative disease, a liver disease, a cancer, a cardiovascular disease, obesity, an inflammatory disease or aging in a subject in need of such treatment, comprising administering to said subject the pharmaceutical formulation or composition as described herein. Applications of TML-6 treatment of these diseases are those as discussed in Min Hao, Yue Chu, Jingxuan Lei, Zhouhui Yao, Pingping Wang, Ziyan Chen, Kuilong Wang, Xianan Sang, Xin Han, Lu Wang, Gang Cao. Pharmacological Mechanisms and Clinical Applications of Curcumin: Update. Aging and illness. 2023, 14 (3): 716-749 https: / / doi.org / 10.14336 / AD.2022.1101, and Su IJ, Chang HY, Wang HC, Tsai KJ. A Curcumin Analog Exhibits Multiple Biological Effects on the Pathogenesis of Alzheimer's Disease and Improves Behavior, Inflammation, and [3-Amyloid Accumulation in a Mouse Model. Int J Mol Sci. July 30, 2020; 21 (15): 5459. doi: 10.3390 / ijms21155459. PMID: 32751716; PMCID: PMC7432838. Examples of neurodegenerative disease include, but are not limited to, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease, and prion diseases.
[0060] The formulation and pharmaceutical composition as described herein have improved solubility and bioavailability characteristics and therefore provide advantageous efficacy in the prevention and / or treatment of a neurodegenerative disease.
[0061] The following examples / studies are presented to assist those skilled in the art in practicing the present invention.
[0062] Formulation Preparation of the Present Disclosure: Wet Granulation
[0063] For the formulations of Examples 1 to 3 (E01 to E03), the components listed in Table 1 were sieved and blended to form granules, then dried and shaped to form the formulation products. In Table 1, TPGS is the abbreviation for PEG-1000 Da-tocopherol succinate, and SDS is the abbreviation for sodium dodecyl sulfate (also referred to as SLS).
[0064] Table 1: components of formulations E01 to E03 Components (% by weight) E01 E02 E03 TML-6 50 50 50 Lactose 200 17 20 7 TPGS 25 25 Tween 80 10 Kollidone VA64 PVP K30 3 3 SDS 25 Crospovidone 5 5 5
[0065] Preparation of formulation of the present disclosure: solid dispersion with evaporation of the solvent
[0066] For the formulations of Examples 4 to 12 (E04 to E12), the components listed in Table 2 were dispersed in the solvent (purified water, 95% ethanol and / or acetone), and the resulting dispersions were dried in an oven. After cooling, the dry dispersion was ground and sieved.
[0067] Table 2: components of formulations E04 to E12 Components (% by weight) E04 E05 E06 E07 E08 E09 E10 Eli E12 TML-6 47.50 33.33 22.22 33.33 18.18 23.70 23.46 31.00 29.33 Poly(butyl methacrylate-co-2-dimethylaminoethyl-co-methyl methacrylate) 1 / 2 / 1 47.50 HPMC E5 LV 36.36 47.40 46.92 Poloxamer 18 8 18.18 23.70 23.46 62.00 58.65 Tween 80 1.00 1.00 Kollidone VA6 4 33.33 PVP K30 33.33 44.44 SDS 5.00 MCC102 33.34 33.34 27.38 MCC101 25.00 Aerosil 200 1.00 1.00 1.00 Crospovidone 5.00 5.20 5.16 5.00 5.02
[0068] Preparation of formulation of the present disclosure: spray drying
[0069] The components of the formulation of Example 13 (E13) are as indicated in Table 1.
[0070] Table 3: components of formulation E13 [Tables 3] API TML-6, 10.5 g Polymer Methacrylic acid-ethyl acrylate copolymer (1 / 1) 19.5 g Solvent Acetone / EtOH = 95 / 5% v / v / 1500 ml API / polymer ratio 35 / 65% w / w, solid cone: 2% in solvent
[0071] The above components were mixed and the resulting mixture was sprayed using a spray dryer and then the spray-dried powder was collected.
[0072] The formulations of Examples 14 to 17 were prepared with the same spray drying process, and their components are as shown in Table 4.
[0073] Table 4: components of formulations E13 to E17 [Tables 4] Components (% by weight) E13 E14 E15 E16 E17 TML-6 35 70 80 70 70 Poly(methacrylic acid-co-ethyl acrylate) 1 / 1 65 30 20 10 HPMC 20 30
[0074] X-ray powder diffraction (XRPD) studies
[0075] TML-6 (unformulated) and TML-6 formulation E13 were analyzed on the sample holder without background and presented for X-ray analysis. The XRPD pattern of TML-6 ([Fig.l]) showed reflections from 20 (± 0.2° 20) to 5.5°, 11.1°, 15.7°, 16.7°, 22.3°, etc., indicating the crystalline state.
[0076] The XRPD pattern of TML-6 E13 formulation ([Fig.4]) was virtually continuous, with no sharp or narrow diffraction peaks, indicating an amorphous form.
[0077] Differential scanning calorimetry (DSC) studies
[0078] A sample (1-2 mg) was accurately weighed into an aluminum pan and sealed, then heated from 40 to 160°C at a heating rate of 10°C / min for DSC analysis.
[0079] The DSC thermogram of TML-6 ([Fig.3]) was characterized by an abrupt endothermic peak at 134.25°C, corresponding to its melting point in the crystalline state.
[0080] The DSC thermograms of TML-6 formulations E14 to E17 ([Fig.3]) showed a broad peak at a temperature of about 50°C to about 90°C, corresponding to the melting point of the excipients (possible shift), and the characteristic peak of crystalline TML-6 is not present.
[0081] The DSC melting points of TML-6 formulations E10 and E12 ([Fig.5]) did not show any significant exothermic or endothermic peak, also indicating an amorphous form.
[0082] The DSC thermogram of the TML-6 E04 formulation ([Fig.4]) showed an endothermic peak at 132.55°C, close to that of TML-6 (about 132.85°C), indicating the crystalline state.
[0083] Dissolution test in 0.1 N HCl and phosphate buffer pH 6.8, 30 minutes
[0084] The dissolution of TML-6 (API alone) and TML-6 formulations (E01 to E12) was measured in media simulating gastric juices for 30 minutes, and the results are as shown in Tables 5 and 6. The dissolution of TML-6 (API alone) and TML-6 formulations (E13 to E17) was measured in media simulating intestinal juices for 30 minutes, and the results are as shown in Table 6.
[0085] Table 5: dissolution of TML-6 formulations (E01 to E12) Vehicle / Polymer Formulation Ratio Solid Form Dissolutio n in 30 minu tes API Medium Alone TML-6 Crystalline 0.1% HCl 0.1 N E01 TML-6 / TPGS (2 / 1) + PVP K30 Crystalline 1.1% HCl 0.1 N E02 TML-6 / TPGS (2 / 1) Crystalline 1.1% HCl 0.1 N E03 TML-6 / SLS / Tween 80 (1 / 0.5 / 0.2) + PV PK30 Crystalline 1.1% HCl 0.1 N E04 TML-6 / poly(butyl methacrylate-co-2-dimethylaminoethyl methacrylate e)-co-methyl methacrylate) 1 / 2 / 1 (1 / 1) Crystalline 6.1% HCl 0.1 N E05 TML-6 / PVP K30 (1 / 1) Crystalline 3.7% HCl 0.1 N + 0.2% SLS E06 TML-6 / PVP K30 (1 / 2) Crystalline 2.6 HCl 0.1 N + 0.2% SLS E07 TML-6 / Kollidone VA64 (1 / 1) Crystalline 3.9% HCl 0.1 N + 0.2% SLS E08 TML-6 / HPMC / P188 (1 / 2 / 1) Amorphous 60.1% HCl 0.1 N + 0.2% SLS E09 TML-6 / HPMC / P188 (1 / 2 / 1) Amorphous 68.2% HCl 0.1 N + 0.5% SLS E10 TML-6 / HPMC / P188 (1 / 2 / 1) Amorphous 88.5% HCl 0.1 N + 0.2% SLS Eli TML-6 / Poloxamer 188 (1 / 2) Amorphous 85.0% HCl 0.1 N + 0.2% SLS E12 TML-6 / HPMC / P188 (1 / 2 / 1) Amorphous 87.7% HCl 0.1 N + 0.2% SLS
[0086] Table 6: Dissolution of TML-6 formulations (SDO to SD3 and SD5) Formulation ratio TML-6 / methacrylic acid copolymer / ethyl acrylate (1 / 1) / HPMC Solid form Dissolves in 30 minutes API medium alone 100 / 0 / 0 Crystalline 0.06% Phosphate buffer pH 6.8 E13 35 / 65 / 0 Amorphous 98.7% Phosphate buffer pH 6.8 + 1% SLS E14 70 / 30 / 0 Amorphous 97.7% E15 80 / 20 / 0 Amorphous 93.6% E16 70 / 10 / 20 Amorphous 57.5% E17 70 / 0 / 30 Amorphous 39.8%
[0087] With reference to Tables 5 and 6 above, the addition of a polymethacrylate-based copolymer, a poly(methacrylic acid)-based copolymer, a poloxamer and / or a cellulose-derived excipient can effectively improve the dissolution of TML-6. Furthermore, TML-6 exhibits better dissolution in amorphous form than in crystalline form.
[0088] Pharmacokinetic (PK) studies in rats
[0089] The objective of this study is to obtain the pharmacokinetic profiles of TML-6 API (unformulated, crystalline), TML-6 E02 formulation (crystalline) and TML-6 E10, E12 and E13 formulations (amorphous) in oral doses (PO) when administered to 6-8 week old male Sprague-Dawley rats (BioLASCO Taiwan Co. Ltd.). The methodology was five doses to rats. The animals received a single dose of TML-6 API, TML-6 E02, E10, E12 and E13 formulations at 25 mg / kg by oral gavage.
[0090] Preparation of administration solutions: The oral formulations of TML-6 API, E02, E10, E12 and E13 were prepared by suspending these formulated TML6 powders in the aqueous vehicle composed of 0.5% methylcellulose (MC) up to a concentration of 2.5 mg / ml of TML-6 respectively.
[0091] Plasma Sample Preparation and Bioanalysis: Blood samples were serially withdrawn from all animals via tail veins. Blood samples of approximately 0.2 ml were collected at each of the following time points: before administration and 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 24 hours after administration. Plasma separation was performed by centrifugation (1000 xg for 15 minutes at 4°C) after blood sampling. Plasma TML-6 concentrations in rats were determined by liquid chromatography-tandem mass spectrometry (LC-MS / MS), as shown in Figures 6 and 7. The lower limit of quantification (LLOQ) was 0.1 ng / ml. Plasma concentration-time data above the LLOQ at each dose level were used in the calculation of TML-6 PK parameters (Table 7).
[0092] Results: PK studies of TML-6 API and TML-6 E02, E10, E12 and E13 formulations were performed after oral administration to rats of 25 mg / kg in a 0.5% MC suspension. The Cmax and AUQo 00) of ML-6 API and TML-6 E02, E10, E12 and E13 formulations are summarized in Table 7. There was no significant difference in Cmax and AUCo æ among unformulated TML-6 (TML-6 API) and TML-6 E02 formulation. TML-6 E10, E12 and E13 formulations can help to improve the Cmax and AUC(0-æ) of TML-6. The results also showed that formulations with better dissolution of TML-6 also have better Cmax and AUQoæ.
[0093] Table 7: Summary of Cmax and AUC(0°°) of TML-6 in rats after oral doses Route Solid form Dose (mg / kg) Cmax (ng / ml) AUC(0 æ, (ng*h / ml) API alone PO Crystalline 25.0 25.3 73.6 E02 PO Crystalline 25.0 19.8 82.9 E10 PO Amorphous 25.0 142 256 E12 PO Amorphous 25.0 144 250 E13 PO Amorphous 25.0 178 267
[0094] The compositions and methods of the disclosure each have several novel aspects, none of which alone is responsible for or necessary for the desirable attributes disclosed herein. The various methods and features described above may be used independently of one another or may be combined in various ways. ways. All possible combinations and subcombinations are intended to fall within the scope of this disclosure. Various modifications of the implementations described in this disclosure may be readily identified by those skilled in the art, and the generic principles defined herein may be applied to other implementations without departing from the spirit or scope of this disclosure. Thus, the claims are not intended to be limited to the implementations illustrated herein, but are to be given the broadest scope consistent with this disclosure, the principles, and the novel features disclosed herein.
[0095] Certain features described in this disclosure in the context of separate implementations may also be implemented in combination in a single implementation. Conversely, various features described in the context of a single implementation may also be implemented in multiple implementations separately or in any suitable subcombination. Furthermore, although features may be described above as operating in certain combinations and even initially claimed as such, one or more features of a claimed combination may in some cases be deleted from the combination, and the claimed combination may be directed to a subcombination or variation of a subcombination. No feature or group of features is necessary or indispensable to every embodiment.
Claims
Claims
1. A formulation comprising TML-6 or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof in amorphous form, and one or more excipients, TML-6.
2. A formulation according to claim 1, characterized by a differential scanning calorimetry thermogram which does not include any abrupt endothermic peaks.
3. Formulation according to claim 1 or 2, characterized by a DSC thermogram which does not include an endothermic peak corresponding to crystalline TML-6.
4. A formulation according to any one of claims 1 to 3, characterized by a DSC thermogram which includes a broad endothermic peak at a temperature of about 50°C to about 90°C.
5. A formulation according to claim 1, characterized by an X-ray powder diffraction (XRPD) pattern that is substantially continuous (without a narrow or sharp diffraction peak).
6. A formulation according to claim 5, characterized by an XRPD pattern that does not include a 20 degree reflection (± 0.2° 20) at one or more of 5.5°, 11.1°, 15.7°, 16.7°, and 22.3°.
7. A formulation comprising from about 20% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof, and from about 10% (w / w) to about 80% (w / w) of one or more excipients,
8.
9.
10.
11.
12.
13.
14. TML-6. The formulation of claim 7, wherein TML-6, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, is in amorphous form. A formulation according to claim 7 or 8, which comprises from about 70% (w / w) to 90% (w / w) of TML-6, or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof, and from about 10% (w / w) to about 30% (w / w) of one or more excipients. A formulation according to any one of claims 7 to 9, wherein the excipient(s) comprise enteric polymers. A formulation according to any one of claims 7 to 10, wherein the excipient(s) comprise at least one of a polymethacrylate-based copolymer, a poly(methacrylic acid)-based copolymer, a poloxamer and a cellulose-derived excipient. The formulation of claim 11, wherein the ratio of polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymer to cellulose-derived excipients is in the range of about 1:5 to about 5:
1. A formulation according to claim 11 or 12, wherein the amount of the polymethacrylate-based copolymer and / or poly(methacrylic acid)-based copolymers is in the range of about 10% to about 70% (w / w), and the amount of the cellulose-derived excipient is in the range of about 10% to about 70% (w / w). Formulation according to any one of claims 11 to 13, wherein the polymethacrylate-based copolymer and / or the poly(methacrylic acid)-based copolymer are selected from the group consisting of: poly(methacrylic acid, methacrylate
15. methyl methacrylate) 1 / 1, poly(methacrylic acid, ethyl acrylate) 1 / 1, poly(methacrylic acid, methyl methacrylate) 1 / 2, poly(methacrylic acid, methyl methacrylate) 1 / 2, a polymer of methyl acrylate, methyl methacrylate and methacrylic acid, poly(butyl methacrylate-co-2-dimethylaminoethyl methacrylate-co-methyl methacrylate) 1 / 2 / 1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.2, poly(ethyl acrylate, methyl methacrylate, methacrylate chloride 2-trimethylammonioethyl or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.2, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.2, poly(ethyl acrylate, methyl methacrylate,2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.1, poly(ethyl acrylate, methyl methacrylate, 2-trimethylammonioethyl methacrylate chloride or 2-(methacryloyloxy)-N,N,N-trimethylethanaminium chloride) 1 / 2 / 0.1, poly(ethyl acrylate, methyl methacrylate) with 0.7% PEG stearyl ether 2 / 1, poly(ethyl acrylate, methyl methacrylate methyl) with 1.5% nonoxynol 2 / 1 and poly(ethyl acrylate, methyl methacrylate) with 1.5% (nonoxynol) 2 / 1, and combinations thereof., A formulation according to any one of claims 7 to 14, wherein the cellulose-derived excipient is selected from the group consisting of cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylmethylcellulose, a cellulose ester derivative, cellulose acetate, cellulose acetate phthalate, cellulose acetate butyrate, cellulose acetate propionate, hydroxypropylmethylcellulose phthalate, microcrystalline cellulose, hydroxyethylcellulose and hydroxypropylmethylcellulose.
16. A formulation according to any one of claims 7 to 15, wherein the formulation is in the form of tablets, granules, capsules or spray-dried powders.
17. A pharmaceutical composition comprising the formulation of any one of claims 1 to 16 and one or more additional excipients.
18. The pharmaceutical composition of claim 17, wherein the additional excipient(s) include, but are not limited to, diluents, disintegrants, binding agents, lubricants, and glidants.
19. A formulation according to any one of claims 1 to 16 or a pharmaceutical composition according to claim 17 or 18, for use in the prevention and / or treatment of a neurodegenerative disease, liver disease, cancer, cardiovascular disease, obesity, inflammatory disease or aging in a subject in need of such treatment.
20. A pharmaceutical formulation or composition for use according to claim 19, wherein the neurodegenerative disease is amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's chorea, multiple system atrophy, dementia, motor neuron disease, Creutzfeldt-Jakob disease or prion disease.
